Food Regulation. Neal D. Fortin
Чтение книги онлайн.

Читать онлайн книгу Food Regulation - Neal D. Fortin страница 88

Название: Food Regulation

Автор: Neal D. Fortin

Издательство: John Wiley & Sons Limited

Жанр: Техническая литература

Серия:

isbn: 9781119764298

isbn:

СКАЧАТЬ exist, do the studies that have the most reliable methodologies suggest a particular outcome?

       If multiple studies exist, what do most studies suggest or find? Does the totality of the evidence agree with the claim(s)?

      * * * * *

      However, medical food is a narrow and special category. Medical food claims must be based on therapeutic or chronic medical needs. For instance, foods for those with genetic metabolic disorders. A medical food must be intended for a patient who has a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements.

      While some diseases benefit from the consumption of certain types of foods, if those foods are available as part of a healthy diet and the nutrients within those foods are able to be absorbed by the patient, then the foods would not be considered medical foods. Rather, medical foods are foods that are specially formulated and processed for a patient who requires use of the product as a major component of a disease or condition’s specific dietary management. For example, vitamin C to cure or prevent the scurvy is not a medical food because the disease can be cured or prevented with a healthy diet. On the other hand, a food that eliminates or significantly restricts phenylalanine for treatment of phenylketonuria could be considered a medical food.

      A subcategory of health claims is drug claims. A drug claim is a claim that states or implies that a product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.

      A product with an unapproved drug claim may result in multiple violations of the FD&C Act. The most obvious potential violation is the prohibition on false or misleading claims, but this is the least of the concerns. FDA has far easier options than being drawn into a factual battle over the quality and the quantity of scientific research supporting a therapeutic claim. Specifically, FDA is more likely to bring actions for violation as follows:

       Marketing an unapproved new drug.68

       Misbranding a drug by failing to include adequate directions for use.69

      FDA may bring both charges against a product with unapproved therapeutic claims. This is sometimes referred to as the FDA “double squeeze.”

      5.9.1 Marketing an Unapproved New Drug

      5.9.2 Misbranded Drug Violations Based on Inadequate Directions for Use

      Notes

      1 1 21 C.F.R. § 101.14(a)(1).

      2 2 21 C.F.R. § 101.14(c).

      3 3 FDA, Qualified Health Claims: Letter of Enforcement Discretion—Walnuts and Coronary Heart Disease (Mar. 9, 2004) (Docket No. 02P‐0292).

      4 4 21 C.F.R. § 101.14(e).

      5 5 A disease means damage to an organ, part, structure, or system of the body such that it does not function properly (e.g., cardiovascular disease), or a state of health leading to dysfunction (e.g., hypertension). See 21 C.F.R. § 101.93(g) regarding disease and dietary supplements.

      6 6 FDCA § 403(r)(3)(A)(ii).

      7 7 21 C.F.R. § 101.14(a)(4).

      8 8 21 C.F.R. § 101.14(e)(6).

СКАЧАТЬ